Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Thermo Fisher forecasts 2024 below estimates, cautious on biotech demand

Published 01/31/2024, 06:28 AM
Updated 01/31/2024, 02:06 PM
© Reuters. FILE PHOTO: A company flag flies outside the offices of Thermo Fisher Scientific offices in Waltham, Massachusetts, U.S., August 2, 2023. REUTERS/Brian Snyder/File Photo

By Bhanvi Satija

(Reuters) -Thermo Fisher Scientific on Wednesday forecast annual profit and revenue below Wall Street estimates, signaling that a slump in demand for its services used to make therapies and vaccines will extend at least into the first half of the year.

The medical equipment maker also said it does not expect demand in its key market, China, to improve this year. Thermo's shares fell nearly 4%, dragging down peers Danaher (NYSE:DHR) and Agilent Technologies (NYSE:A) more than 1%.

Analysts said the company's 2024 forecast was largely in-line with its expectations laid out in October, while at least two said the forecast was conservative.

"They've been burned before by not being cautious enough," said Bernstein analyst Eve Burstein.

Thermo Fisher (NYSE:TMO) witnessed sluggish demand last year for its bioprocessing services used to make therapeutics and vaccines, as its biotech clients reined in spending on drug development due to higher interest rates.

Thermo Fisher CEO Marc Casper said biotech clients seem more optimistic than the last five quarters.

"They love the M&A activity that was happening at the end of the year that gets investors excited about new company formation, new rounds of capital," said Casper.

The funding environment for biotechs is "probably stabilizing", said Paul Knight, an analyst at KeyBanc Capital Markets, citing a strong year of regulatory approvals.

"We've got this really strong backdrop of approvals from the U.S. Food and Drug Administration, which ultimately drive research and production," said Knight.

Thermo Fisher forecast annual revenue in a range of $42.1 billion to $43.3 billion, shy of analysts' expectations of $42.93 billion at midpoint, according to LSEG data.

© Reuters. FILE PHOTO: A company flag flies outside the offices of Thermo Fisher Scientific offices in Waltham, Massachusetts, U.S., August 2, 2023. REUTERS/Brian Snyder/File Photo

The company expects to earn between $20.95 and $22.00 per share in 2024, below analysts' expectations of $22.04.

Yet, the medical equipment maker posted quarterly adjusted profit of $5.67 per share came in 3 cents ahead of analysts' estimates, helped in part by its cost-reduction measures and higher sales of analytical tools.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.